The vitamin does not increase metabolic rate, enhance fat burning, or improve the appetite suppression that drives semaglutide weight loss
The key requirement is that the compound must not be essentially a copy of a commercially available drug
Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques
IQVIA estimates that at least one in three people living with obesity worldwide resides in a country where semaglutide is available off-patent in 2026
Absorption and distribution characteristics were optimal for subcutaneous administration, with the drug reaching therapeutic concentrations within the expected timeframe and maintaining consistent exposure throughout the dosing interval
Recognized adverse effects include cholelithiasis, gastrointestinal disturbances, and reductions in lean mass [10,11,12]